Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1988 Nov;74(2):166–170.

Interleukin-3 and interleukin-4 each strongly inhibit the induction and function of human LAK cells.

G Gallagher 1, F Wilcox 1, F al-Azzawi 1
PMCID: PMC1541800  PMID: 3265653

Abstract

We have examined some of the factors which may regulate the generation and function of human lymphokine-activated killer (LAK) cells. In particular we have studied the effect of cytokines other than interleukin-2 on the ability of human LAK cells to kill human tumour cells. By exposing human tumour cells to human LAK-cells in the presence and absence of interleukin-3 or interleukin-4, we were able to demonstrate that each of these cytokines was able to severely reduce the amount of tumour cell killing. Additionally, we examined the effect of interleukin-3 or interleukin-4 on the production in vitro of human LAK cells by including these materials with interleukin-2 while LAK-cells were being induced. These results showed that not only were these cytokines able to inhibit human LAK-cell function, but they were also able to strongly reduce the ability of interleukin-2 to generate human LAK-cells.

Full text

PDF
166

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Azzawi F., Stimson W. H., Govan A. D. Human antibodies to ovarian cancer antigens secreted by lymphoblastoid cell lines. J Clin Lab Immunol. 1987 Feb;22(2):71–75. [PubMed] [Google Scholar]
  2. Gallagher G., Taylor N., Willdridge J. Separate but complementary roles for the two forms of interleukin 1 in the growth of transformed human B lymphoblasts. Scand J Immunol. 1987 Sep;26(3):295–301. doi: 10.1111/j.1365-3083.1987.tb02263.x. [DOI] [PubMed] [Google Scholar]
  3. Ihle J. N., Weinstein Y. Immunological regulation of hematopoietic/lymphoid stem cell differentiation by interleukin 3. Adv Immunol. 1986;39:1–50. doi: 10.1016/s0065-2776(08)60347-8. [DOI] [PubMed] [Google Scholar]
  4. Johnson W. J., Adams D. O. Assays detecting the antibody-dependent and independent binding and cytolysis of tumor cells by murine macrophages. Methods Enzymol. 1986;132:555–568. doi: 10.1016/s0076-6879(86)32041-x. [DOI] [PubMed] [Google Scholar]
  5. Kalland T., Belfrage H., Bhiladvala P., Hedlund G. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. J Immunol. 1987 Jun 1;138(11):3640–3645. [PubMed] [Google Scholar]
  6. Kalland T. Physiology of natural killer cells. In vivo regulation of progenitors by interleukin 3. J Immunol. 1987 Dec 1;139(11):3671–3675. [PubMed] [Google Scholar]
  7. Kradin R. L., Kurnick J. T. Adoptive immunotherapy of cancer with activated lymphocytes and interleukin-2. Pathol Immunopathol Res. 1986;5(3-5):193–202. doi: 10.1159/000157013. [DOI] [PubMed] [Google Scholar]
  8. Lee F., Yokota T., Otsuka T., Meyerson P., Villaret D., Coffman R., Mosmann T., Rennick D., Roehm N., Smith C. Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities. Proc Natl Acad Sci U S A. 1986 Apr;83(7):2061–2065. doi: 10.1073/pnas.83.7.2061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mulé J. J., Smith C. A., Rosenberg S. A. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J Exp Med. 1987 Sep 1;166(3):792–797. doi: 10.1084/jem.166.3.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rosenberg S. A. Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today. 1988 Feb;9(2):58–62. doi: 10.1016/0167-5699(88)91261-3. [DOI] [PubMed] [Google Scholar]
  11. Rosenberg S. A., Lotze M. T. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol. 1986;4:681–709. doi: 10.1146/annurev.iy.04.040186.003341. [DOI] [PubMed] [Google Scholar]
  12. Spits H., Yssel H., Takebe Y., Arai N., Yokota T., Lee F., Arai K., Banchereau J., de Vries J. E. Recombinant interleukin 4 promotes the growth of human T cells. J Immunol. 1987 Aug 15;139(4):1142–1147. [PubMed] [Google Scholar]
  13. Tilden A. B., Itoh K., Balch C. M. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. J Immunol. 1987 Feb 15;138(4):1068–1073. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES